# US 2026/0248844 A1 · Compositions and methods to disinfect, treat and prevent microbial infections

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0248844 A1
- Document ID: US20260248844A1
- Status: Published application
- Kind: A1
- Application number: 19/540,110
- Filed: 2026-02-13
- Published: 2026-08-27
- Earliest claimed: 2020-07-07
- Assignees: Wiab Water Innovation AB
- Applicants: Wiab Water Innovation AB
- Inventors: Pål Rongved; Aina Kristin Pham; Thomas Bjarnsholt
- Web page: https://patentgrep.com/patent/US20260248844A1

## CPC

- A61K 33/20: Elemental chlorine; Inorganic compounds releasing chlorine
- A61P 31/14: for RNA viruses
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention provides stable antimicrobial and disinfectant compositions comprising use of a solid precursor of an oxidized state of chlorine. The invention also provides on-demand storage and mixing vessels and methods for preparing and delivering on demand formulations. In addition, the invention provides antiviral, antibiotic and general antimicrobial uses, in vivo, on surfaces and via spray applications.

## Claims

### Claim at position 1

1-20. (canceled)

### Claim 21

An isotonic inhalation formulation comprising from about 50 ppm to about 500 ppm of HOCl and from about 0.08 wt % to about 0.5 wt % of a pharmaceutically acceptable acid having a pKa between about 3 and about 5 and a diluent, wherein the formulation has a pH of 4.3-6.0.

### Claim 22 (depends on 21)

The isotonic inhalation formulation according to claim 21, wherein the pharmaceutically acceptable acid is acetic acid.

### Claim 23 (depends on 21)

The isotonic inhalation formulation according to claim 21, wherein the diluent is water or saline.

### Claim 24 (depends on 22)

The isotonic inhalation formulation according to claim 22, wherein the isotonic formulation comprises from 50 ppm to 500 ppm of HOCl and from 0.08 wt % to 0.5 wt % of acetic acid, wherein the formulation has a pH of 4.3-6.0.

### Claim 25 (depends on 21)

The isotonic inhalation formulation according to claim 21, wherein the formulation comprises:
a. from 50 ppm to 500 ppm of HOCl,
b. about 0.25 wt % of acetic acid; and
c. about 0.9% NaCl and/or about 5% glucose,
wherein the formulation has a pH of about pH 5.3.

### Claim 26 (depends on 21)

The isotonic inhalation formulation according to claim 21, wherein the formulation is prepared for administration orally or by nasal inhalation.

### Claim 27

A method of treating an airway infection in a subject in need thereof, the method comprises administering an effective amount of an isotonic formulation comprising from about 50 ppm to about 500 ppm of HOCl and a pharmaceutically acceptable organic acid, and a diluent, wherein the formulation has a pH of 4.3-6.0.

### Claim 28 (depends on 27)

The method according to claim 27, wherein the pharmaceutically acceptable organic acid is acetic acid.

### Claim 29 (depends on 27)

The method according to claim 27, wherein the isotonic formulation comprises from about 10 ppm to about 500 ppm of HOCl and from about 0.08 wt % to about 0.5 wt % of acetic acid, wherein the formulation has a pH of 4.3-6.0.

### Claim 30 (depends on 27)

The method according to claim 27, wherein the isotonic formulation comprises about 100 ppm of HOCl and from about 0.08 wt % to about 0.5 wt % of acetic acid and a diluent, wherein the formulation has a pH of 4.3-6.0.

### Claim 31 (depends on 27)

The method according to claim 27, wherein the isotonic formulation comprises about 200 ppm of HOCl and from about 0.08 wt % to about 0.5 wt % of acetic acid and a diluent, wherein the formulation has a pH of 4.3-6.0.

### Claim 32 (depends on 27)

The method according to claim 27, wherein the isotonic formulation comprises about 500 ppm of HOCl and from about 0.08 wt % to about 0.5 wt % of acetic acid and a diluent, wherein the formulation has a pH of 4.3-6.0.

### Claim 33 (depends on 27)

The method according to claim 27, wherein the isotonic formulation comprises from about 10 ppm to about 500 ppm of HOCl and about 0.25 wt % of acetic acid and a diluent, wherein the formulation has a pH of 4.3-6.0.

### Claim 34 (depends on 27)

The method according to claim 27, wherein the isotonic formulation comprises from about 10 ppm to about 500 ppm of HOCl and about 0.5 wt % of acetic acid and a diluent, wherein the formulation has a pH of 4.3-6.0.

### Claim 35 (depends on 27)

The method according to claim 27, wherein the isotonic formulation comprises:
a. from 50 ppm to 500 of HOCl,
b. about 0.25 wt % of acetic acid; and
c. about 0.9 wt % NaCl and/or about 5 wt % glucose,
wherein the formulation has a pH of about pH 5.3.

### Claim 36 (depends on 27)

The method according to claim 27, wherein the method comprises preparing the composition for administration using a device configured to release a suitable amount of the composition, the device comprising:
a. a first compartment comprising NaOCl or Ca(OCl)2,
b. a second compartment comprising a pharmaceutically acceptable organic acid; and
c. optionally, a third compartment comprising water or saline.

### Claim 37 (depends on 27)

The method according to claim 27, wherein the isotonic formulation is administered by inhalation.

### Claim 38 (depends on 27)

The method according to claim 27, wherein the infection is a lung infection.

### Claim 39 (depends on 38)

The method according to claim 38, wherein the lung infection is a bacterial lung infection.

### Claim 40 (depends on 39)

The method according to claim 39, wherein the bacterial lung infection is caused by a pathogenic gram-positive, or a pathogenic gram-negative bacteria.

### Claim 41 (depends on 27)

The method according to claim 27, wherein the infection is caused by S. aureus, P. aeruginosa, E. coli, E. faecium or A. baumannii.

### Claim 42 (depends on 27)

The method according to claim 27, wherein the infection is a pathogenic fungi lung infection.

### Claim 43 (depends on 42)

The method according to claim 42, wherein the pathogenic fungi lung infection is caused by C. albicans or A. brasiliensis.

### Claim 44 (depends on 27)

The method according to claim 27, wherein the subject is a human patient suffering from ventilator associated pneumonia (VAP).
